MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock upon...
$188,657K
Net proceeds from
issuance of common stock
$34,035K
Proceeds from the
exercise of stock options
$13,604K
Proceeds from issuance of
common stock from espp
$1,584K
Net cash provided by
financing activities
$217,963K
Effect of exchange
rates on cash
$87K
Canceled cashflow
$19,917K
Net increase
(decrease) in cash, cash...
-$34,778K
Canceled cashflow
$218,050K
Maturities of short-term
investments
$252,469K
Stock-based compensation
expense
$66,818K
Accounts payable,
accrued expenses and...
$21,892K
Non-cash interest
expense
$20,584K
Depreciation and
amortization
$1,338K
Non-cash rent expense
$428K
Other non-cash items
-$90K
Repayment of deferred
royalty obligation
$19,917K
Net cash used in
investing activities
-$137,153K
Canceled cashflow
$252,469K
Net cash used in
operating activities
-$115,675K
Canceled cashflow
$111,150K
Total revenues
$189,757K
Other (income)
expense, net
-$1,264K
Purchases of short-term
investments
$348,669K
Acquisition of ipr&d assets
$40,000K
Purchases of property and
equipment
$953K
Net loss
-$196,539K
Canceled cashflow
$191,021K
Accounts receivable
$7,570K
Inventory
$7,474K
Non-cash accretion &
amortization of short-term...
-$6,516K
Prepaid expenses and
other current assets
$6,327K
Deferred revenue
-$1,092K
Change in fair value of
embedded derivative...
-$910K
Other long-term
assets, net
$397K
Global headcount
expense
$172,648K
Preclinical, clinical and
development expense
$87,322K
Commercial & medical
affairs
$66,963K
Corporate, general &
administrative
$35,348K
Cost of sales
$19,492K
Interest (income)
expense, net
-$5,290K
Income taxes
$497K
Back
Back
Cash Flow
source: myfinsight.com
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)